AR043972A1 - Formulaciones farmaceuticas de fsh y lh - Google Patents

Formulaciones farmaceuticas de fsh y lh

Info

Publication number
AR043972A1
AR043972A1 ARP040101138A ARP040101138A AR043972A1 AR 043972 A1 AR043972 A1 AR 043972A1 AR P040101138 A ARP040101138 A AR P040101138A AR P040101138 A ARP040101138 A AR P040101138A AR 043972 A1 AR043972 A1 AR 043972A1
Authority
AR
Argentina
Prior art keywords
fsh
pharmaceutical formulations
formulations
hormone
luteinizing hormone
Prior art date
Application number
ARP040101138A
Other languages
English (en)
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33135521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043972(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of AR043972A1 publication Critical patent/AR043972A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere al campo de formulaciones farmacéuticas de hormona de estimulación de folículos (FSH), hormona luteinizante (LH), y mezclas de FSH y hormona luteinizante (LH), y los métodos para producir dichas formulaciones.
ARP040101138A 2003-04-02 2004-04-02 Formulaciones farmaceuticas de fsh y lh AR043972A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100882 2003-04-02
EP03101543 2003-05-27
EP03101828 2003-06-20

Publications (1)

Publication Number Publication Date
AR043972A1 true AR043972A1 (es) 2005-08-17

Family

ID=33135521

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101138A AR043972A1 (es) 2003-04-02 2004-04-02 Formulaciones farmaceuticas de fsh y lh

Country Status (25)

Country Link
US (1) US7741268B2 (es)
EP (1) EP1610822B2 (es)
JP (1) JP4699991B2 (es)
KR (1) KR101105486B1 (es)
AR (1) AR043972A1 (es)
AT (1) ATE492292T2 (es)
AU (1) AU2004226666B9 (es)
BR (1) BRPI0409532B8 (es)
CA (1) CA2518903C (es)
CY (1) CY1111291T1 (es)
DE (1) DE602004030673D1 (es)
DK (1) DK1610822T4 (es)
EA (1) EA012565B1 (es)
HK (1) HK1086503A1 (es)
HR (1) HRP20100727T4 (es)
IL (1) IL171151A (es)
ME (1) ME00217B (es)
MX (1) MXPA05010635A (es)
NO (1) NO330214B1 (es)
NZ (1) NZ542247A (es)
PL (1) PL1610822T5 (es)
PT (1) PT1610822E (es)
RS (2) RS20050737A (es)
SI (1) SI1610822T2 (es)
WO (1) WO2004087213A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
EP1951395B1 (en) 2005-09-14 2012-02-29 Ares Trading S.A. Method for the quantitative determination of poloxamers
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8664369B2 (en) * 2007-11-01 2014-03-04 Merck Serono S.A. LH liquid formulations
EA019530B1 (ru) * 2008-02-08 2014-04-30 Биодженерикс Аг Жидкая лекарственная форма фсг
CN101269215B (zh) * 2008-05-15 2011-03-23 上海天伟生物制药有限公司 一种糖蛋白激素组合物
CN102309747B (zh) * 2008-09-17 2013-04-17 上海天伟生物制药有限公司 高纯度绝经期促性腺素冻干针剂
US8329649B2 (en) * 2008-11-04 2012-12-11 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone and histidine
KR101761168B1 (ko) 2009-04-01 2017-07-25 바이오제너릭스 게엠베하 재조합 ｆｓｈ 정제 방법
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
WO2011076117A1 (zh) * 2009-12-22 2011-06-30 上海天伟生物制药有限公司 绝经期促性腺素组合物
WO2012127500A2 (en) * 2011-03-11 2012-09-27 Sanzyme Limited Composition for spermatogenesis
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EA201690626A1 (ru) * 2013-11-12 2016-09-30 Кадила Хелзкэр Лимитед Новый состав гонадотропинов
US9920107B2 (en) * 2014-05-23 2018-03-20 Instituto Massone S.A. Process for obtaining HMG-UP (human menopausal gonadotropin with ultra-purity grade) and a composition free of contaminants
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
GB1065127A (en) * 1963-03-11 1967-04-12 Serono Ist Farm Pituitary gonadotropic hormone preparation and method for its production
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS5921613A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4780451B1 (en) 1987-01-23 1995-04-04 Asua International Inc Composition and method for producing superovulation in cattle
US5162306A (en) 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE3863908D1 (de) 1987-11-27 1991-08-29 Akzo Nv Stabilisierung von antikoerpern.
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5087615A (en) 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US5508261A (en) 1991-06-18 1996-04-16 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
DE69231129D1 (de) 1991-06-18 2000-07-06 Univ New Jersey Med Analoga von glykoproteinhormonen mit geänderter rezeptorbindungsspezifität und aktivität und verfahren zur darstellung und verwendung derselben
IT1250075B (it) 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5356876A (en) * 1992-01-13 1994-10-18 Trinity University Methods of terminating pregnancy
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
CA2337745C (en) 1992-07-31 2005-04-12 Genentech, Inc. Human growth hormone aqueous formulation
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
ATE178789T1 (de) 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
DE69528080T2 (de) 1994-12-22 2003-06-05 Ortho Pharma Corp Lösliche arzneizusammensetzungen enthaltend 2-chloro-2'-deoxyadenosine
CA2214889C (en) * 1995-03-10 2005-05-24 Hans Koll Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
CN102416176A (zh) 1995-07-27 2012-04-18 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
IL124004A (en) 1995-11-07 2003-10-31 Genentech Inc Stable pharmaceutical composition comprising ngf
CN1244109A (zh) 1996-12-23 2000-02-09 诺沃挪第克公司 用于储存液体药物的线型烯烃聚合物药物容器
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
WO1998030592A1 (en) 1997-01-10 1998-07-16 Epicyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20010007673A1 (en) 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
EP0996429B1 (en) 1997-10-27 2003-02-05 MERCK PATENT GmbH Solid state solutions and dispersions of poorly water soluble drugs
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US20020165146A1 (en) * 1998-07-23 2002-11-07 Hoffman James Arthur FSH article of manufacture
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
EP1113799A4 (en) 1998-09-17 2004-06-09 Lilly Co Eli PROTEIN-BASED PREPARATION
DE60043106D1 (de) 1999-06-30 2009-11-19 Takeda Pharmaceutical Polypeptide und deren dna
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
EP1471891A4 (en) 2002-02-08 2007-04-11 Alkermes Inc POLYMER-BASED COMPOSITIONS FOR PROLONGED RELEASE

Also Published As

Publication number Publication date
HK1086503A1 (en) 2006-09-22
HRP20100727T1 (en) 2011-02-28
SI1610822T1 (sl) 2011-02-28
AU2004226666B9 (en) 2010-04-08
RS20050737A (en) 2007-11-15
ATE492292T2 (de) 2011-01-15
EP1610822B2 (en) 2018-09-19
BRPI0409532B1 (pt) 2019-09-17
AU2004226666B2 (en) 2009-09-03
BRPI0409532B8 (pt) 2021-05-25
PL1610822T5 (pl) 2019-05-31
WO2004087213A8 (en) 2005-03-17
US20060147480A1 (en) 2006-07-06
EP1610822B1 (en) 2010-12-22
KR20050110037A (ko) 2005-11-22
US7741268B2 (en) 2010-06-22
CA2518903A1 (en) 2004-10-14
CY1111291T1 (el) 2015-08-05
KR101105486B1 (ko) 2012-01-13
WO2004087213A1 (en) 2004-10-14
RS57872B1 (sr) 2018-12-31
EP1610822A1 (en) 2006-01-04
EA012565B1 (ru) 2009-10-30
NZ542247A (en) 2008-03-28
ME00217B (me) 2011-02-10
IL171151A (en) 2014-11-30
DK1610822T3 (da) 2011-01-31
NO330214B1 (no) 2011-03-07
SI1610822T2 (sl) 2018-12-31
JP4699991B2 (ja) 2011-06-15
CA2518903C (en) 2013-02-05
JP2006522072A (ja) 2006-09-28
EA200501531A1 (ru) 2006-06-30
NO20054982L (no) 2005-10-26
BRPI0409532A (pt) 2006-04-18
DK1610822T4 (en) 2019-01-14
DE602004030673D1 (de) 2011-02-03
MXPA05010635A (es) 2005-12-12
MEP31708A (en) 2010-10-10
AU2004226666A1 (en) 2004-10-14
PL1610822T3 (pl) 2011-06-30
HRP20100727T4 (hr) 2018-11-16
PT1610822E (pt) 2011-01-05

Similar Documents

Publication Publication Date Title
AR043972A1 (es) Formulaciones farmaceuticas de fsh y lh
TW200637614A (en) Bendamustine pharmaceutical compositions
HN2002000266A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
BRPI0416743A (pt) formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
AR052238A1 (es) Formulacion de tabletas estables
CR10582A (es) Metodos para tratar canceres usando formas poliformicas de 3-(-4-amino-1,3, dihidro-isoindol-2-il)-piperidina-2,6 dione (divisional exp. 8146)
TW200511444A (en) Strained-silicon-on-insulator single-and double-gate MOSFET and method for forming the same
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
BRPI0415505A (pt) agente terapêutico para mesotelioma
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
UY27982A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
CY1114121T1 (el) Λυοφιλοποιημενα σκευασματα fsh/lh
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
AU2003255820A8 (en) Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
DE60318716D1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
DOP2003000587A (es) AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
CL2004001067A1 (es) Compuestos derivados de benzotiazol; procedimiento de preparacion; medicamentos que los contiene; y su uso en el tratamiento de enfermedades relacionadas con el receptor de adenosina a2a.
EA200601030A1 (ru) 7α,17α-ЗАМЕЩЁННЫЕ 11β-ГАЛОГЕНОСТЕРОИДЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ НА ИХ ОСНОВЕ

Legal Events

Date Code Title Description
FC Refusal